<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 5.0.1.2 [11/04/2012 03:03:13 AM] by DataTracks -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Wednesday, November 14, 2012 07:03:20 AM -->
<xbrli:xbrl xmlns:tglp="http://www.tonglipharma.com/20120930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="tglp-20120930.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_FYE_31-Mar-2008_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_GovernmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-04-01
</xbrli:startDate>
<xbrli:endDate>
2008-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:TonghuaAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-04-01
</xbrli:startDate>
<xbrli:endDate>
2010-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:TonghuaAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_31-Dec-2010_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">us-gaap:IndividualMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-12-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_31-Mar-2011_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">us-gaap:IndividualMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-01
</xbrli:startDate>
<xbrli:endDate>
2011-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Sep-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-07-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Sep-2011_ProductOrServiceAxis_PanaxAndRadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:PanaxAndRadixPolygoniCapsuleMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-07-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Sep-2011_ProductOrServiceAxis_AntihyperlipidemicsMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:AntihyperlipidemicsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-07-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Sep-2011_ProductOrServiceAxis_CalciumGluconateOralLiquidMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:CalciumGluconateOralLiquidMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-07-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Sep-2011_ProductOrServiceAxis_AntiBacterialMouthwashMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:AntiBacterialMouthwashMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-07-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2011_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:XinyuBreathSprayPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2011_ProductOrServiceAxis_PanaxAndRadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:PanaxAndRadixPolygoniCapsuleMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2011_ProductOrServiceAxis_AntihyperlipidemicsMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:AntihyperlipidemicsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2011_ProductOrServiceAxis_CalciumGluconateOralLiquidMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:CalciumGluconateOralLiquidMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2011_ProductOrServiceAxis_AntiBacterialMouthwashMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:AntiBacterialMouthwashMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2011_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_HarbinTianmuRealEstateDevelopmentCoLtdMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:HarbinTianmuRealEstateDevelopmentCoLtdMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoMingliChairmanOfCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:YaoMingliChairmanOfCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_UsHuaSkyInternationalInvestmentLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:UsHuaSkyInternationalInvestmentLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_TianmuInvestmentCoLtdMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:TianmuInvestmentCoLtdMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_MaterialContractAxis_TonghuaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:MaterialContractAxis">tglp:TonghuaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_MaterialContractAxis_XinyuMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:MaterialContractAxis">tglp:XinyuMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoYuanShareholderOfCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:YaoYuanShareholderOfCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_MaterialContractAxis_YangsenwubaoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:MaterialContractAxis">tglp:YangsenwubaoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>


<xbrli:context id="Context_3ME_30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Sep-2012_ProductOrServiceAxis_RadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:RadixPolygoniCapsuleMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_6ME_30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:TonghuaAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_FirstInstallmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:TonghuaAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsInstallmentsAxis">tglp:FirstInstallmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_SecondInstallmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:TonghuaAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsInstallmentsAxis">tglp:SecondInstallmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_ThirdInstallmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:TonghuaAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsInstallmentsAxis">tglp:ThirdInstallmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_FourthInstallmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:TonghuaAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsInstallmentsAxis">tglp:FourthInstallmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:XinyuBreathSprayPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_ProductOrServiceAxis_RadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">tglp:RadixPolygoniCapsuleMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_YangshenWubaoPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:YangshenWubaoPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_HarbinTianmuRealEstateDevelopmentCoLtdMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:HarbinTianmuRealEstateDevelopmentCoLtdMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoMingliChairmanOfCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:YaoMingliChairmanOfCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_UsHuaSkyInternationalInvestmentLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:UsHuaSkyInternationalInvestmentLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_TianmuInvestmentCoLtdMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:TianmuInvestmentCoLtdMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_MaterialContractAxis_TonghuaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:MaterialContractAxis">tglp:TonghuaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_MaterialContractAxis_XinyuMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:MaterialContractAxis">tglp:XinyuMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoYuanShareholderOfCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tglp:YaoYuanShareholderOfCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_MaterialContractAxis_YangsenwubaoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="tglp:MaterialContractAxis">tglp:YangsenwubaoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Sep-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>XUI~\FVPYwivc444c555cT{h>6<HE<4GG1FH<:18F651FFH;1:=H5=G<6G96I -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="CNY"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_6ME_30-Sep-2012">Tongli Pharmaceuticals (USA), Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_6ME_30-Sep-2012">0001052284</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_6ME_30-Sep-2012">--03-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_6ME_30-Sep-2012">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:TradingSymbol contextRef="Context_6ME_30-Sep-2012">tglp</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_08-Nov-2012" unitRef="shares" decimals="0">14848122</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_6ME_30-Sep-2012">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="Context_6ME_30-Sep-2012">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="Context_6ME_30-Sep-2012">2012-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Context_6ME_30-Sep-2012">Q2</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Context_6ME_30-Sep-2012">2012</dei:DocumentFiscalYearFocus>
<us-gaap:Cash contextRef="Context_As_Of_31-Mar-2011" unitRef="USD" decimals="0">592671</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_30-Sep-2011" unitRef="USD" decimals="0">111362</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">23508</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">94661</us-gaap:Cash>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">4166178</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">4288904</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">13613</us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">49851</us-gaap:InventoryNet>
<us-gaap:AdvancesOnInventoryPurchases contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">1016294</us-gaap:AdvancesOnInventoryPurchases>
<us-gaap:AdvancesOnInventoryPurchases contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">950546</us-gaap:AdvancesOnInventoryPurchases>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">241738</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">50631</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:DeferredTaxAssetsNetCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">399081</us-gaap:DeferredTaxAssetsNetCurrent>
<us-gaap:DeferredTaxAssetsNetCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">187254</us-gaap:DeferredTaxAssetsNetCurrent>
<us-gaap:DepositsAssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">3189441</us-gaap:DepositsAssetsCurrent>
<us-gaap:DepositsAssetsCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">2769426</us-gaap:DepositsAssetsCurrent>
<us-gaap:DueFromRelatedPartiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">87538</us-gaap:DueFromRelatedPartiesCurrent>
<us-gaap:DueFromRelatedPartiesCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:DueFromRelatedPartiesCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">9137391</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">8391273</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">6193526</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">6081576</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">469726</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">10704284</us-gaap:AssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">11405456</us-gaap:AssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">19841675</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">19796729</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">429117</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">171279</us-gaap:AccountsPayableCurrent>
<us-gaap:TaxesPayableCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">879386</us-gaap:TaxesPayableCurrent>
<us-gaap:TaxesPayableCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">263642</us-gaap:TaxesPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">192340</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">218162</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DueToRelatedPartiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">0</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:DueToRelatedPartiesCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">66209</us-gaap:DueToRelatedPartiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">1500843</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">719292</us-gaap:LiabilitiesCurrent>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">13295</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">14728</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">8842699</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">9056266</us-gaap:AdditionalPaidInCapital>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">2075975</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">2278898</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">7408863</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">7727545</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">18340832</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">19077437</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">19841675</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">19796729</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Sep-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">1000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30-Sep-2012" unitRef="shares" decimals="0">1000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30-Sep-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30-Sep-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Sep-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30-Sep-2012" unitRef="shares" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">13294778</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30-Sep-2012" unitRef="shares" decimals="0">14728111</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="shares" decimals="0">13294778</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30-Sep-2012" unitRef="shares" decimals="0">14728111</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">3891052</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">9455886</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">3330990</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">3330990</us-gaap:SalesRevenueGoodsNet>
<us-gaap:CostOfGoodsSold contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">2096058</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">5092500</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">1747908</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">1747908</us-gaap:CostOfGoodsSold>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">1794994</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">4363386</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">1583082</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">1583082</us-gaap:GrossProfit>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">918107</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1135130</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">130122</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">633715</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">89601</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">175639</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">91060</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">182298</us-gaap:DepreciationAndAmortization>
<us-gaap:SellingExpense contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">35914</us-gaap:SellingExpense>
<us-gaap:SellingExpense contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">106429</us-gaap:SellingExpense>
<us-gaap:SellingExpense contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">213852</us-gaap:SellingExpense>
<us-gaap:SellingExpense contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">232918</us-gaap:SellingExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">1043622</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1417198</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">435034</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">1048931</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">751372</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">2946188</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">1148048</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">534151</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">14220</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">28153</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">-238</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-263</us-gaap:InterestExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">-14220</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-28153</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">238</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">263</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">737152</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">2918035</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">1148286</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">534414</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">399789</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">980364</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">345894</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">215732</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">337363</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1937671</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">802392</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">318682</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">235809</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">478501</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">-30900</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">202924</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_30-Sep-2011" unitRef="USD" decimals="0">573172</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">2416172</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_30-Sep-2012" unitRef="USD" decimals="0">771492</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">521606</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_30-Sep-2011" unitRef="USD_per_Share" decimals="2">0.03</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_6ME_30-Sep-2011" unitRef="USD_per_Share" decimals="2">0.16</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_30-Sep-2012" unitRef="USD_per_Share" decimals="2">0.06</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_6ME_30-Sep-2012" unitRef="USD_per_Share" decimals="2">0.02</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_30-Sep-2011" unitRef="shares" decimals="0">11926485</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_6ME_30-Sep-2011" unitRef="shares" decimals="0">11849039</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_30-Sep-2012" unitRef="shares" decimals="0">13569415</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_6ME_30-Sep-2012" unitRef="shares" decimals="0">13470734</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">174452</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">178409</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">103286</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">105679</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:OtherNoncashExpense contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">28153</us-gaap:OtherNoncashExpense>
<us-gaap:OtherNoncashExpense contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:OtherNoncashExpense>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">773500</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">215000</us-gaap:ShareBasedCompensation>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-2805</us-gaap:DeferredIncomeTaxExpenseBenefit>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">215732</us-gaap:DeferredIncomeTaxExpenseBenefit>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1867914</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">78152</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1890848</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">36121</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">44877</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-193571</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-138858</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-262644</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-529097</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-605646</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-1457337</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">321207</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-1088744</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-712702</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1088744</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-416535</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromRelatedPartyDebt>
<us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">161197</us-gaap:ProceedsFromRelatedPartyDebt>
<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">201127</us-gaap:RepaymentsOfRelatedPartyDebt>
<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfRelatedPartyDebt>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-201127</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">161197</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">88411</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">5284</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-481309</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">71153</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1157729</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 6pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 48px;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;ORGANIZATION AND BASIS OF PRESENTATION&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Tongli Pharmaceuticals (USA), Inc.(the &amp;#8220;Company&amp;#8221;), through an indirect wholly-owned subsidiary, Harbin Tianmu Pharmaceuticals Co., Ltd. (&amp;#8220;Tianmu Pharmaceuticals&amp;#8221;), develops, produces and sells a wide variety of pharmaceuticals and healthcare products in the People&amp;#8217;s Republic of China (&amp;#8220;PRC&amp;#8221; or &amp;#8220;China&amp;#8221;) that are based on traditional Chinese medicine (&amp;#8220;TCM&amp;#8221;). In August 2011, the Company formed Harbing Lvnong Plant Ltd. (&amp;#8220;Lvnong&amp;#8221;) to plant and sell herbs in China. Lvnong is 100% owned by the Company&amp;#8217;s indirect wholly-owned subsidiary, Heilongjiang Tongli Technology Co., Ltd. (&amp;#8220;Tongli Technology&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and pursuant to the requirements for reporting on Form 10-Q. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year or any other periods. The information included in this Form 10-Q should be read in conjunction with Management&amp;#8217;s Discussion and Analysis of Financial Condition and Results of Operations and the financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2012.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The balance sheet as of March 31, 2012 has been derived from the audited financial statements of the Company as of that date, but does not include all of the information and footnotes required by U.S. GAAP for the complete financial statements.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-left: 0px; width: 48px; padding-right: 0px; font-size: 10pt; font-weight: bold;"&gt;2.&lt;/td&gt;
&lt;td style="padding-left: 0px; padding-right: 0px; font-size: 10pt; font-weight: bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Principles of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The consolidated financial statements include the accounts of: (i) the Company (ii) the Company&amp;#8217;s wholly owned subsidiary American Tony Pharmaceuticals, Inc., a Delaware corporation (&amp;#8220;American Tony&amp;#8221;), (iii) American Tony&amp;#8217;s wholly owned subsidiary Tongli Technology, and (iv) Tongli Technology&amp;#8217;s wholly owned subsidiaries, Tianmu Pharmaceuticals and Lvnong, each PRC companies.&amp;#160;&amp;#160;All significant inter-company accounts and transactions have been eliminated upon consolidation.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Uses of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period.&amp;#160;&amp;#160;Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company adopted ASC 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Level 3-Inputs are unobservable inputs which reflect the reporting entity&amp;#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The carrying amounts reported in the balance sheets for cash, accounts receivable, inventory, prepaid expense, accounts payable and other accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC 820.&lt;/p&gt;
&lt;p style="text-align: left; background-color: white; margin-top: 0pt; font: 10pt times new roman, times, serif; margin-bottom: 0pt;"&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin-top: 0pt; font: 10pt times new roman, times, serif; margin-bottom: 0pt;"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Inventory is stated at the lower of cost, determined using the weighted average cost method, and net realizable value.&amp;#160;&amp;#160;Costs include materials, labor and manufacturing overhead.&amp;#160;&amp;#160;Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.&amp;#160;&amp;#160;Management periodically compares the cost of inventory with the market value and an allowance is made for writing down the inventory to its market value, if lower than cost. No allowance for inventory markdown is considered necessary for six months ended September 30, 2012 and 2011.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Harvested Chinese herbs inventories are stated at lower of cost or market. Cost of growing herbs includes director labor and material costs accumulated through the balance sheet date.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px;
 font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Long-lived assets, which include property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the assets.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company accounts for the impairment of long-lived assets in accordance with the guidance of FASB ASC 360-10-20. Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable.&amp;#160;&amp;#160;For assets that are to be held and used, impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value.&amp;#160;&amp;#160;If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.&amp;#160;&amp;#160;Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable.&amp;#160;&amp;#160;Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. Based on its review, the Company believes that, as of September 30, 2012, there were no impairment of its long-lived assets.&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Deferred income taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company accounts for income taxes in accordance with FASB ASC 740 &amp;#8220;&lt;i&gt;Income Taxes&amp;#8221; &lt;/i&gt;which requires that deferred tax assets and liabilities be recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&amp;#160;&amp;#160;In addition, ASC 740 requires recognition of future tax benefits, such as carry-forwards, to the extent that realization of such benefits is more likely than not and that a valuation allowance be provided when it is more likely than not that some portion of the deferred tax asset will not be realized. Management reviews this valuation allowance periodically and makes adjustments as warranted.&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Foreign currency translation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Since the Company operates primarily in the PRC, the Company&amp;#8217;s functional currency is the Chinese Renminbi (&amp;#8220;RMB&amp;#8221;).&amp;#160;&amp;#160;For financial reporting purposes, RMB has been translated into United States dollars (&amp;#8220;USD&amp;#8221;) as the reporting currency.&amp;#160;&amp;#160;Equity accounts are translated at historical rates. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders' equity as &amp;#8220;Accumulated other comprehensive income&amp;#8221;. Gains and losses resulting from foreign currency translations are included in accumulated other comprehensive income.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="color: black;"&gt;Revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, and no other significant obligations of the Company exist and collectability is reasonably assured. &lt;/font&gt;Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from&lt;font style="color: black;"&gt; customers. The Company sells primarily to distributors who subsequently sell the merchandise. The agreements with distributors do not provide for the right of return.&amp;#160;&amp;#160;Return from distributors has historically been immaterial and accordingly no reserve is deemed necessary as of September 30, 2012 and 2011.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:InventoryDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;INVENTORY&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of September 30, 2012 and March 31, 2012, inventory consists the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;March 31, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;49,790&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;13,553&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;61&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;60&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;49,851&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;13,613&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
<us-gaap:DepositLiabilitiesDisclosuresTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table align="center" style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;4.&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;CONTRACT DEPOSIT&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Contract deposit represents payments under material contracts by which the Company intends to purchase drug formula to be used in the manufacturing and increasing its product lines.&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="color: black;"&gt;As of September 30, 2012 and March 31, 2012, contract deposit consists&lt;/font&gt; of&lt;font style="color: black;"&gt; the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;September 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 70%; font-size: 10pt;"&gt;Contract deposit-Tonghua (1)&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;2,294,667&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;3,444,658&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;Contract deposit-Xinyu(2)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;214,509&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;Contract deposit-Yangshenwubao (3)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;474,759&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2,769,426&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3,659,167&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;Less: current portion&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(3,189,441&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,769,426&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;469,726&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="background-color: white; margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(1)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;On March 21, 2010, the Company entered into a New Drug Assignment Agreement (the &amp;#8220;Tonghua Agreement&amp;#8221;) with TonghuaYisheng Pharmaceuticals Company Limited (&amp;#8220;Tonghua&amp;#8221;) pursuant to which the Company agreed to purchase a new drug candidate, called Nafarelin, from Tonghua for a purchase price of RMB33,000,000 (approximately $4.85 million). The total purchase price is payable in three installments: 33% of the total purchase price (approximately $1.6 million) was paid upon execution of the Tonghua Agreement in March 2010; another 33% (approximately $1.6 million) was paid in March 2011 (although it is required to be paid upon conclusion of third clinical trial for the product pursuant to the terms of the Tonghua Agreement) and the balance is payable upon conclusion of the transfer.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;Nafarelin is a proposed treatment for endometriosis and prostate cancer. At a minimum, completion of the third phase clinical trail is a pre-condition to receipt of the New Drug Approval Certificate from the SFDA. The SFDA new drug approval procedure is separate and distinct from the patent prosecution procedure. To date, neither Tonghua nor the Company has applied or intend to apply for patent protection for Nafarelin or the formula or process related to Nafarelin. Once Tonghua is granted the New Drug Approval Certificate for Nafarelin, according to pharmaceutical laws of PRC, the Company, as the assignee of the New Drug Approved Certificate, shall receive 4 years of exclusive protection. As described below, the Company regards such protection period as the appropriate amortization period. The patent protection is irrelevant for purposes of amortization in determining the life of the drug as the Company will not apply for patent protection for Nafarelin.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;The Company is not be responsible for conducting or paying for any clinical trial and/or research and development in connection with the new drug application for Nafarelin. Pursuant to the Tonghua Agreement, Tonghua shall continue the research, development and clinical trial work for Nafarelin until the SFDA grants the New Drug Approval Certificate and the product is ready to be marketed. Tonghua is listed as the applicant for the SFDA new drug approval process for this product. Once SFDA approval is obtained, the Company will be able to consummate the assignment and enjoy the protection afforded by the New Drug Approval Certificate. In addition, the Company&amp;#8217;s ability to commercialize this new product also requires assistance and cooperation from Tonghua, which Tonghua is obligated to provide to us under the Tonghua Agreement.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;Under PRC law, the SFDA&amp;#8217;s New Drug Approval Certificate grants certain exclusive protections to approved new drugs, meaning that the subject formula may not be manufactured by other parties in China. The exclusive protection periods for the new drugs vary from 4 to 12 years depending on the category of the new drug. Because the Company shall be the beneficiary of the exclusive protection during the applicable period (the so-called &amp;#8220;new drug approval period&amp;#8221;), upon consummation of the transaction contemplated by the Tonghua Agreement, the Company will regard the protection period as the appropriate amortization period. Based on ASC 805-50-30 &amp;#8220;Initial Measurement on Acquisition of Assets Rather Than a Business&amp;#8221; and ASC350-30 &amp;#8221;General Intangibles Other Than Goodwill&amp;#8221;, the total payment pursuant to the Tonghua Agreement will be recorded as an intangible asset once the Company obtains the SFDA New Drug Approval Certificate and will be amortized over the term of the new drug protection period.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;Based on a written mutual understanding between the Company and Tonghua, any payments the Company made to Tonghua under the Tonghua Agreement will be refunded if SFDA approval is not obtained for Nafarelin. Such mutual understanding, although the Company believes to be binding, was not explicitly stipulated in the Tonghua Agreement or otherwise memorialized. As such, the first two installment under the Tonghua Agreement was accounted as a deposit and the remaining last installment payment will be also accounted as deposits until the New Drug Approval Certificate is obtained, at which point the total payment will be recorded as intangible asset and amortized over the term of the new drug protection period.The Tonghua Agreement also provides that the Company and Tonghua will compensate one another for all losses incurred by the other party if the purchase is not concluded due to reasons attributable to the offending party.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;On June 6, 2012, the Company entered into a Termination Agreement with Tonghua pursuant to which the Tonghua Agreement was terminated. Pursuant to the Termination Agreement, Tonghua will refund prepayment of RMB 22,000,000 (approximate to $3.5 million) in four installments. The first installment of RMB5, 000,000 (approximately $794,000) will be refunded prior to August 30, 2012, the second installment of RM6, 000,000 (approximately $950,000) will be refunded prior to November 30, 2012, the third installment of RMB8,000,000 (approximately $1.3 million) will be refunded prior to February 28, 2013 and the last installment of RMB3,000,000 (approximately $476,000) will be refunded prior to May 30, 2013. During six months ended September 30, 2012, the Company received refund payment of RMB7,500,000 (approximately $1.19 million).&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: justify; width: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 48px; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; (2)&lt;/td&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;On April 30, 2012, the Company entered into Xinyu Breath Spray purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the total purchase price is RMB8,500,000 (approximately $1.33 million). The Company will pay 50% of the purchase price after commencement of the Xinyu Breath Spray purchase agreement and pay the rest of the purchase price after the Company manufactured three batches of Xinyu Breath Spray that meet the quality standards of the product. The Company paid RMB1,370,000 (approximately $215,000) on March 29, 2012, RMB3,630,000 (approximately $568,000) on May 30, 2012 and paid the balance due of RMB3,500,000 (approximately $554,000) in August 2012. &lt;font style="color: black;"&gt;Based on ASC 805-50-30 &amp;#8220;Initial Measurement on Acquisition of Assets Rather Than a Business&amp;#8221; and ASC350-30 &amp;#8221;General Intangibles Other Than Goodwill&amp;#8221;, the total payment pursuant to the &lt;/font&gt;agreement&lt;font style="color: black;"&gt; with Harbin Junde Healthcare Product Company is recorded as an intangible asset and will be amortized over the estimated useful life of this product. (See note 5)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="background-color: white; margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(3)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;On August 10, 2012, the Company entered into Yangshen Wubao purchase agreement with Harbin Junde Healthcare product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the Yangshen Wubao at the total purchase price of RMB13,000,000 (approximately $2.06 million). The Company paid RMB3,000,000 (approximately $475,000) as the deposit at the closing of Yangsheng Wubao purchase agreement. The rest of the purchase price will be paid in installments according to the payment schedule. The Company is planning to manufacture this product using a subcontractor in the United States. Currently, the Company is in the process of testing this product. &lt;font style="color: black;"&gt;Based on ASC 805-50-30 &amp;#8220;Initial Measurement on Acquisition of Assets Rather Than a Business&amp;#8221; and ASC350-30 &amp;#8221;General Intangibles Other Than Goodwill&amp;#8221;, the total payment pursuant to the agreement will be recorded as an intangible asset once the company finish the acquisition process and &lt;/font&gt;is being&lt;font style="color: black;"&gt; amortized over the life of this product.&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DepositLiabilitiesDisclosuresTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 6pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="text-align: left; width: 48px;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;DUE TO (FROM) RELATED PARTIES&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Due to/(from) related parties consist of the following:&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;September 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 70%; font-size: 10pt;"&gt;Due from Harbin Tianmu Real Estate Development Co. Ltd (a)&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;(398,260&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;(599,151&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Due to Yao, Mingli, Chairman of the Company&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;570,324&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;570,324&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Due to(from) US Hua Sky International Investment LLC (b)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(23,901&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;27,727&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Due from Tianmu Investment Co. Ltd (c)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(4,748&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(7,829&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;Due from Yao, Yuan, a shareholder of the Company (d)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(77,206&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(78,609&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;66,209&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;(87,538&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(a) Harbin Tianmu Real Estate Development Co., Ltd. is an entity owned by our Chairman, Mr. Mingli Yao.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(b) US Hua Sky International Investment LLC is an entity owned by our Chairman, Mr. Mingli Yao&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(c)Tianmu Investment Co., Ltd. is an entity partially owned by our Chairman, Mr. Mingli Yao.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(d) Ms. Yuan Yao is the daughter of Mr. Mingli Yao.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Mr. Mingli Yao has personally guaranteed the loan receivable from Harbin Tianmu Real Estate Development Co. Ltd and Tianmu Investment Co. Ltd. If the loan has not been repaid in the year ended March 31, 2013, Mr. Yao has agreed to offset the balance due to him referenced above.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table style="font: 10pt/normal times new roman, times, serif; margin-top: 0px; margin-bottom: 6pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="width: 48px; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On May 10, 2012, the Company issued 133,333 common shares to its legal counsel Ellenoff Grossman &amp;amp; Schole LLP for services rendered. The Company recorded the fair value of $20,000 for these issued shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On September 20, 2012, the Company issued 1,300,000 shares of common stock to a consultant for services performed and three salesmen for sales commission. The Company recorded the fair value of $195,000 for these issued shares.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;8.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;TAXES&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(a)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Corporation income tax (&amp;#8220;CIT&amp;#8221;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company&amp;#8217;s Chinese subsidiaries are governed by the Income Tax Law of the People&amp;#8217;s Republic of China concerning the private-run enterprises, which are generally subject to tax at a new statutory rate of 25%. As of September 30, 2012, for the Company&amp;#8217;s PRC entities remain open for statutory examination by PRC tax authorities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company is incorporated in the United States. It had net operating loss carry forwards for United States income tax purposes amounted to $1,988,399 and $1,871,117 for the six months ended September 30, 2012 and the year ended March 31, 2012 respectively, which may be available to reduce future years' taxable income in the United States. These carry forwards will expire between 2028 and 2030. Management doesn't expect to remit any of its net income back to the United States in the foreseeable future. Accordingly, the Company recorded a full valuation allowance as of September 30, 2012 and March 31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The reconciliation of income tax expense at the U.S. statutory rate at 35% in 2012 and 2011, to the Company&amp;#8217;s effective tax is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;U.S. Statutory income tax rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;187,045&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,021,313&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Taxable difference between U.S. and China&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(84,670&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(319,368&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expenses not deductable for tax purpose in China&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;172,125&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;113,357&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;106,294&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Effective income tax&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;215,732&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;980,364&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The provisions for income taxes for the six months ended September 30, 2012 and the years ended March 31, 2012 are summarized as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Current&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;983,169&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Deferred - United States&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(109,298&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Deferred - China&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;211,673&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(2,805&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Change in Valuation Allowance&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;113,357&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;215,732&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;980,364&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The components of income (loss) before income taxes from China and U.S. for the six months ended September 30, 2012 and 2011 were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;For the Six Months Ended September 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;China&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;666,696&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3,193,681&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;United States&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(132,282&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(275,646&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Income before income tax&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;534,414&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,918,035&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(b)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Value added tax (&amp;#8220;VAT&amp;#8221;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Enterprises or individuals who sell commodities, engage in repair and maintenance or import or export goods in the PRC are subject to a value added tax in accordance with the PRC laws. The value added tax standard rate is 17% of the gross sales price. A credit is available whereby VAT paid on the purchases of semi-finished products or raw materials used in the production of the Company&amp;#8217;s finished products can be used to offset the VAT due on the sales of the finished products.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(c)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Other taxes&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company is also subject to 5% of business tax, 7% of City Construction Tax and 5% of Education Fees based on VAT.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table align="center" style="width: 100%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;9.&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On June 28, 2012, the Company signed the lease agreement for the Company&amp;#8217;s office which will have a rental arrangement of $1,749 per month. Pursuant to the lease agreement, the term of the lease is from August 2012 to July 2013. Four months rental were waived. In June, 2012, the Company paid $3,498 as security deposit. As of September 30, 2012, the Company was obligated to pay $12,243 under the lease agreement.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<tglp:UnusualRisksAndUncertaintiesDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-left: 0px; width: 48px; padding-right: 0px; font-size: 10pt; font-weight: bold;"&gt;11.&lt;/td&gt;
&lt;td style="padding-left: 0px; padding-right: 0px; font-size: 10pt; font-weight: bold;"&gt;VULNERABILITY DUE TO OPERATIONS IN PRC&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company&amp;#8217;s operations may be adversely affected by significant political, economic and social uncertainties in the PRC. Although the PRC government has been pursuing economic reform policies for more than thirty years, no assurance can be given that the PRC government will continue to pursue such policies or that such policies may not be significantly altered, especially in the event of a change in leadership, social or political disruption or unforeseen circumstances affecting the PRC&amp;#8217;s political, economic and social conditions. There is also no guarantee that the PRC government&amp;#8217;s pursuit of economic reforms will be consistent or effective.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Substantially all of the Company&amp;#8217;s businesses are transacted in RMB, which is not freely convertible. The Peoples Bank of China or other banks are authorized to buy and sell foreign currencies at the exchange rates quoted by the Peoples Bank of China. Approval of foreign currency payments by the Peoples Bank of China or other institutions requires submitting a payment application form together with suppliers&amp;#8217; invoices, shipping documents and signed contracts.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Since the Company has its primary operations in the PRC, the majority of its revenues will be settled in RMB, not U.S. Dollars. Due to certain restrictions on currency exchanges that exist in the PRC, the Company&amp;#8217;s ability to use revenue generated in RMB to pay any dividend payments to its shareholders outside of China may be limited.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company&amp;#8217;s business depends on maintaining licenses of its current products from SFDA. Obtaining licenses for additional products can be expensive and is usually time consuming. Failure to obtain the required licenses can cause the Company&amp;#8217;s business plan to be delayed. If the delays prevent the Company from generating positive cash flows or introducing a significant number of products, there will be a material adverse effect on the Company.&lt;/p&gt;</tglp:UnusualRisksAndUncertaintiesDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table align="center" style="width: 100%; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 48px; font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;12.&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company has evaluated events after the date of these financial statements through the date that these financial statements were issued and no subsequent event is required to be disclosed.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_6ME_30-Sep-2012">&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Uses of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_6ME_30-Sep-2012">&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company adopted ASC 820, Fair Value Measurements and Disclosures. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Level 3-Inputs are unobservable inputs which reflect the reporting entity&amp;#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The carrying amounts reported in the balance sheets for cash, accounts receivable, inventory, prepaid expense, accounts payable and other accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the consolidated balance sheets at fair value in accordance with ASC 820.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:InventoryPolicyTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Inventory is stated at the lower of cost, determined using the weighted average cost method, and net realizable value.&amp;#160;&amp;#160;Costs include materials, labor and manufacturing overhead.&amp;#160;&amp;#160;Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.&amp;#160;&amp;#160;Management periodically compares the cost of inventory with the market value and an allowance is made for writing down the inventory to its market value, if lower than cost. No allowance for inventory markdown is considered necessary for six months ended September 30, 2012 and 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Harvested Chinese herbs inventories are stated at lower of cost or market. Cost of growing herbs includes director labor and material costs accumulated through the balance sheet date.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Long-lived assets, which include property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the assets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The Company accounts for the impairment of long-lived assets in accordance with the guidance of FASB ASC 360-10-20. Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable.&amp;#160;&amp;#160;For assets that are to be held and used, impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value.&amp;#160;&amp;#160;If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.&amp;#160;&amp;#160;Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable.&amp;#160;&amp;#160;Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. Based on its review, the Company believes that, as of September 30, 2012, there were no impairment of its long-lived assets.&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Deferred income taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company accounts for income taxes in accordance with FASB ASC 740 &amp;#8220;&lt;i&gt;Income Taxes&amp;#8221; &lt;/i&gt;which requires that deferred tax assets and liabilities be recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&amp;#160;&amp;#160;In addition, ASC 740 requires recognition of future tax benefits, such as carry-forwards, to the extent that realization of such benefits is more likely than not and that a valuation allowance be provided when it is more likely than not that some portion of the deferred tax asset will not be realized. Management reviews this valuation allowance periodically and makes adjustments as warranted.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Foreign currency translation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Since the Company operates primarily in the PRC, the Company&amp;#8217;s functional currency is the Chinese Renminbi (&amp;#8220;RMB&amp;#8221;).&amp;#160;&amp;#160;For financial reporting purposes, RMB has been translated into United States dollars (&amp;#8220;USD&amp;#8221;) as the reporting currency.&amp;#160;&amp;#160;Equity accounts are translated at historical rates. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders' equity as &amp;#8220;Accumulated other comprehensive income&amp;#8221;. Gains and losses resulting from foreign currency translations are included in accumulated other comprehensive income.&lt;/font&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, and no other significant obligations of the Company exist and collectability is reasonably assured.Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances fromcustomers. The Company sells primarily to distributors who subsequently sell the merchandise. The agreements with distributors do not provide for the right of return.&amp;#160;&amp;#160;Return from distributors has historically been immaterial and accordingly no reserve is deemed necessary as of September 30, 2012 and 2011.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Principles of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0pt; background: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The consolidated financial statements include the accounts of: (i) the Company (ii) the Company&amp;#8217;s wholly owned subsidiary American Tony Pharmaceuticals, Inc., a Delaware corporation (&amp;#8220;American Tony&amp;#8221;), (iii) American Tony&amp;#8217;s wholly owned subsidiary Tongli Technology, and (iv) Tongli Technology&amp;#8217;s wholly owned subsidiaries, Tianmu Pharmaceuticals and Lvnong, each PRC companies.&amp;#160;&amp;#160;All significant inter-company accounts and transactions have been eliminated upon consolidation.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of September 30, 2012 and March 31, 2012, inventory consists the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;March 31, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;49,790&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;13,553&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;61&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;60&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;49,851&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;13,613&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<tglp:ContractDepositAssetsDisclosuresTableTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="color: black;"&gt;As of September 30, 2012 and March 31, 2012, contract deposit consists&lt;/font&gt; of&lt;font style="color: black;"&gt; the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;September 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 70%; font-size: 10pt;"&gt;Contract deposit-Tonghua (1)&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;2,294,667&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;3,444,658&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;Contract deposit-Xinyu(2)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;214,509&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;Contract deposit-Yangshenwubao (3)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;474,759&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2,769,426&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3,659,167&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;Less: current portion&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(3,189,441&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,769,426&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;469,726&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="background-color: white; margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(1)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;On March 21, 2010, the Company entered into a New Drug Assignment Agreement (the &amp;#8220;Tonghua Agreement&amp;#8221;) with TonghuaYisheng Pharmaceuticals Company Limited (&amp;#8220;Tonghua&amp;#8221;) pursuant to which the Company agreed to purchase a new drug candidate, called Nafarelin, from Tonghua for a purchase price of RMB33,000,000 (approximately $4.85 million). The total purchase price is payable in three installments: 33% of the total purchase price (approximately $1.6 million) was paid upon execution of the Tonghua Agreement in March 2010; another 33% (approximately $1.6 million) was paid in March 2011 (although it is required to be paid upon conclusion of third clinical trial for the product pursuant to the terms of the Tonghua Agreement) and the balance is payable upon conclusion of the transfer.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;Nafarelin is a proposed treatment for endometriosis and prostate cancer. At a minimum, completion of the third phase clinical trail is a pre-condition to receipt of the New Drug Approval Certificate from the SFDA. The SFDA new drug approval procedure is separate and distinct from the patent prosecution procedure. To date, neither Tonghua nor the Company has applied or intend to apply for patent protection for Nafarelin or the formula or process related to Nafarelin. Once Tonghua is granted the New Drug Approval Certificate for Nafarelin, according to pharmaceutical laws of PRC, the Company, as the assignee of the New Drug Approved Certificate, shall receive 4 years of exclusive protection. As described below, the Company regards such protection period as the appropriate amortization period. The patent protection is irrelevant for purposes of amortization in determining the life of the drug as the Company will not apply for patent protection for Nafarelin.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;The Company is not be responsible for conducting or paying for any clinical trial and/or research and development in connection with the new drug application for Nafarelin. Pursuant to the Tonghua Agreement, Tonghua shall continue the research, development and clinical trial work for Nafarelin until the SFDA grants the New Drug Approval Certificate and the product is ready to be marketed. Tonghua is listed as the applicant for the SFDA new drug approval process for this product. Once SFDA approval is obtained, the Company will be able to consummate the assignment and enjoy the protection afforded by the New Drug Approval Certificate. In addition, the Company&amp;#8217;s ability to commercialize this new product also requires assistance and cooperation from Tonghua, which Tonghua is obligated to provide to us under the Tonghua Agreement.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;Under PRC law, the SFDA&amp;#8217;s New Drug Approval Certificate grants certain exclusive protections to approved new drugs, meaning that the subject formula may not be manufactured by other parties in China. The exclusive protection periods for the new drugs vary from 4 to 12 years depending on the category of the new drug. Because the Company shall be the beneficiary of the exclusive protection during the applicable period (the so-called &amp;#8220;new drug approval period&amp;#8221;), upon consummation of the transaction contemplated by the Tonghua Agreement, the Company will regard the protection period as the appropriate amortization period. Based on ASC 805-50-30 &amp;#8220;Initial Measurement on Acquisition of Assets Rather Than a Business&amp;#8221; and ASC350-30 &amp;#8221;General Intangibles Other Than Goodwill&amp;#8221;, the total payment pursuant to the Tonghua Agreement will be recorded as an intangible asset once the Company obtains the SFDA New Drug Approval Certificate and will be amortized over the term of the new drug protection period.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;Based on a written mutual understanding between the Company and Tonghua, any payments the Company made to Tonghua under the Tonghua Agreement will be refunded if SFDA approval is not obtained for Nafarelin. Such mutual understanding, although the Company believes to be binding, was not explicitly stipulated in the Tonghua Agreement or otherwise memorialized. As such, the first two installment under the Tonghua Agreement was accounted as a deposit and the remaining last installment payment will be also accounted as deposits until the New Drug Approval Certificate is obtained, at which point the total payment will be recorded as intangible asset and amortized over the term of the new drug protection period.The Tonghua Agreement also provides that the Company and Tonghua will compensate one another for all losses incurred by the other party if the purchase is not concluded due to reasons attributable to the offending party.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;On June 6, 2012, the Company entered into a Termination Agreement with Tonghua pursuant to which the Tonghua Agreement was terminated. Pursuant to the Termination Agreement, Tonghua will refund prepayment of RMB 22,000,000 (approximate to $3.5 million) in four installments. The first installment of RMB5, 000,000 (approximately $794,000) will be refunded prior to August 30, 2012, the second installment of RM6, 000,000 (approximately $950,000) will be refunded prior to November 30, 2012, the third installment of RMB8,000,000 (approximately $1.3 million) will be refunded prior to February 28, 2013 and the last installment of RMB3,000,000 (approximately $476,000) will be refunded prior to May 30, 2013. During six months ended September 30, 2012, the Company received refund payment of RMB7,500,000 (approximately $1.19 million).&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: justify; width: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 48px; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160; (2)&lt;/td&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;On April 30, 2012, the Company entered into Xinyu Breath Spray purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the total purchase price is RMB8,500,000 (approximately $1.33 million). The Company will pay 50% of the purchase price after commencement of the Xinyu Breath Spray purchase agreement and pay the rest of the purchase price after the Company manufactured three batches of Xinyu Breath Spray that meet the quality standards of the product. The Company paid RMB1,370,000 (approximately $215,000) on March 29, 2012, RMB3,630,000 (approximately $568,000) on May 30, 2012 and paid the balance due of RMB3,500,000 (approximately $554,000) in August 2012. &lt;font style="color: black;"&gt;Based on ASC 805-50-30 &amp;#8220;Initial Measurement on Acquisition of Assets Rather Than a Business&amp;#8221; and ASC350-30 &amp;#8221;General Intangibles Other Than Goodwill&amp;#8221;, the total payment pursuant to the &lt;/font&gt;agreement&lt;font style="color: black;"&gt; with Harbin Junde Healthcare Product Company is recorded as an intangible asset and will be amortized over the estimated useful life of this product. (See note 5)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="background-color: white; margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.25in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;(3)&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;On August 10, 2012, the Company entered into Yangshen Wubao purchase agreement with Harbin Junde Healthcare product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the Yangshen Wubao at the total purchase price of RMB13,000,000 (approximately $2.06 million). The Company paid RMB3,000,000 (approximately $475,000) as the deposit at the closing of Yangsheng Wubao purchase agreement. The rest of the purchase price will be paid in installments according to the payment schedule. The Company is planning to manufacture this product using a subcontractor in the United States. Currently, the Company is in the process of testing this product. &lt;font style="color: black;"&gt;Based on ASC 805-50-30 &amp;#8220;Initial Measurement on Acquisition of Assets Rather Than a Business&amp;#8221; and ASC350-30 &amp;#8221;General Intangibles Other Than Goodwill&amp;#8221;, the total payment pursuant to the agreement will be recorded as an intangible asset once the company finish the acquisition process and &lt;/font&gt;is being&lt;font style="color: black;"&gt; amortized over the life of this product.&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</tglp:ContractDepositAssetsDisclosuresTableTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of September 30, 2012 and March 31, 2012, intangible assets consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;March 31, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Land use rights&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,462,731&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,415,426&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Xinyu breath spray&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,345,150&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,807,881&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,415,426&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Less: Accumulated amortization&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(484,001&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(374,394&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,323,880&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,041,032&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Due to/(from) related parties consist of the following:&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;September 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 70%; font-size: 10pt;"&gt;Due from Harbin Tianmu Real Estate Development Co. Ltd (a)&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;(398,260&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;(599,151&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Due to Yao, Mingli, Chairman of the Company&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;570,324&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;570,324&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Due to(from) US Hua Sky International Investment LLC (b)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(23,901&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;27,727&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Due from Tianmu Investment Co. Ltd (c)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(4,748&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(7,829&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;Due from Yao, Yuan, a shareholder of the Company (d)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(77,206&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(78,609&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;66,209&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;(87,538&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(a) Harbin Tianmu Real Estate Development Co., Ltd. is an entity owned by our Chairman, Mr. Mingli Yao.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(b) US Hua Sky International Investment LLC is an entity owned by our Chairman, Mr. Mingli Yao&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(c)Tianmu Investment Co., Ltd. is an entity partially owned by our Chairman, Mr. Mingli Yao.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(d) Ms. Yuan Yao is the daughter of Mr. Mingli Yao.&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The reconciliation of income tax expense at the U.S. statutory rate at 35% in 2012 and 2011, to the Company&amp;#8217;s effective tax is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;U.S. Statutory income tax rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;187,045&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,021,313&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Taxable difference between U.S. and China&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(84,670&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(319,368&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expenses not deductable for tax purpose in China&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;172,125&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;113,357&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;106,294&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Effective income tax&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;215,732&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;980,364&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The provisions for income taxes for the six months ended September 30, 2012 and the years ended March 31, 2012 are summarized as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Current&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;983,169&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Deferred - United States&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(109,298&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Deferred - China&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;211,673&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(2,805&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Change in Valuation Allowance&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;113,357&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;215,732&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;980,364&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The components of income (loss) before income taxes from China and U.S. for the six months ended September 30, 2012 and 2011 were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;For the Six Months Ended September 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;China&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;666,696&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3,193,681&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;United States&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(132,282&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(275,646&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Income before income tax&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;534,414&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,918,035&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">13553</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">49790</us-gaap:InventoryRawMaterialsNetOfReserves>


<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">60</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">61</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:DepositsAssets contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">3659167</us-gaap:DepositsAssets>
<us-gaap:DepositsAssets contextRef="Context_As_Of_31-Mar-2012_MaterialContractAxis_TonghuaMember" unitRef="USD" decimals="0" id="Item_1">3444658</us-gaap:DepositsAssets>
<us-gaap:DepositsAssets contextRef="Context_As_Of_31-Mar-2012_MaterialContractAxis_XinyuMember" unitRef="USD" decimals="0" id="Item_3">214509</us-gaap:DepositsAssets>
<us-gaap:DepositsAssets contextRef="Context_As_Of_31-Mar-2012_MaterialContractAxis_YangsenwubaoMember" unitRef="USD" decimals="0" id="Item_5">0</us-gaap:DepositsAssets>
<us-gaap:DepositsAssets contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">2769426</us-gaap:DepositsAssets>
<us-gaap:DepositsAssets contextRef="Context_As_Of_30-Sep-2012_MaterialContractAxis_TonghuaMember" unitRef="USD" decimals="0" id="Item_7">2294667</us-gaap:DepositsAssets>
<us-gaap:DepositsAssets contextRef="Context_As_Of_30-Sep-2012_MaterialContractAxis_XinyuMember" unitRef="USD" decimals="0" id="Item_8">0</us-gaap:DepositsAssets>
<us-gaap:DepositsAssets contextRef="Context_As_Of_30-Sep-2012_MaterialContractAxis_YangsenwubaoMember" unitRef="USD" decimals="0" id="Item_9">474759</us-gaap:DepositsAssets>
<tglp:LongTermContractsOrProgramsNameOfContractor contextRef="Context_FYE_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember">TonghuaYisheng Pharmaceuticals Company Limited</tglp:LongTermContractsOrProgramsNameOfContractor>
<tglp:LongTermContractsOrProgramsNameOfContractor contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember">Harbin Junde Healthcare product Company</tglp:LongTermContractsOrProgramsNameOfContractor>
<tglp:LongTermContractsOrProgramsNameOfContractor contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_YangshenWubaoPurchaseAgreementMember">Harbin Junde HealthCare product Company</tglp:LongTermContractsOrProgramsNameOfContractor>
<tglp:LongTermContractsOrProgramsDateOfContractEntered contextRef="Context_FYE_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember">2010-03-21</tglp:LongTermContractsOrProgramsDateOfContractEntered>
<tglp:LongTermContractsOrProgramsDateOfContractEntered contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember">2012-04-30</tglp:LongTermContractsOrProgramsDateOfContractEntered>
<tglp:LongTermContractsOrProgramsDateOfContractEntered contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_YangshenWubaoPurchaseAgreementMember">2012-08-10</tglp:LongTermContractsOrProgramsDateOfContractEntered>
<tglp:LongTermContractsOrProgramsPurchasePrice contextRef="Context_FYE_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="USD" decimals="0">4850000</tglp:LongTermContractsOrProgramsPurchasePrice>
<tglp:LongTermContractsOrProgramsPurchasePrice contextRef="Context_FYE_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="CNY" decimals="0">33000000</tglp:LongTermContractsOrProgramsPurchasePrice>
<tglp:LongTermContractsOrProgramsPurchasePrice contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="USD" decimals="0">1330000</tglp:LongTermContractsOrProgramsPurchasePrice>
<tglp:LongTermContractsOrProgramsPurchasePrice contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="CNY" decimals="0">8500000</tglp:LongTermContractsOrProgramsPurchasePrice>
<tglp:LongTermContractsOrProgramsPurchasePrice contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_YangshenWubaoPurchaseAgreementMember" unitRef="USD" decimals="-4">2060000</tglp:LongTermContractsOrProgramsPurchasePrice>
<tglp:LongTermContractsOrProgramsPurchasePrice contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_YangshenWubaoPurchaseAgreementMember" unitRef="CNY" decimals="0">13000000</tglp:LongTermContractsOrProgramsPurchasePrice>
<tglp:LongTermContractsOrProgramsPurchasePriceDueInOneYearOrLessPercentage contextRef="Context_As_Of_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="pure" decimals="4">0.3300</tglp:LongTermContractsOrProgramsPurchasePriceDueInOneYearOrLessPercentage>
<tglp:LongTermContractsOrProgramsPurchasePriceDueInOneYearOrLess contextRef="Context_As_Of_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="USD" decimals="0">1600000</tglp:LongTermContractsOrProgramsPurchasePriceDueInOneYearOrLess>
<tglp:LongTermContractsOrProgramsPurchasePriceDueInOneYearOrLess contextRef="Context_As_Of_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="CNY" decimals="-3">0</tglp:LongTermContractsOrProgramsPurchasePriceDueInOneYearOrLess>
<tglp:LongTermContractsOrProgramsPurchasePriceDueInYearTwoPercentage contextRef="Context_As_Of_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="pure" decimals="4">0.3300</tglp:LongTermContractsOrProgramsPurchasePriceDueInYearTwoPercentage>
<tglp:LongTermContractsOrProgramsPurchasePriceDueInYearTwo contextRef="Context_As_Of_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="USD" decimals="0">1600000</tglp:LongTermContractsOrProgramsPurchasePriceDueInYearTwo>
<tglp:LongTermContractsOrProgramsPurchasePriceDueInYearTwo contextRef="Context_As_Of_31-Mar-2010_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="CNY" decimals="-3">0</tglp:LongTermContractsOrProgramsPurchasePriceDueInYearTwo>
<tglp:LongTermContractsOrProgramsDateOfContractCancelled contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember">2012-06-06</tglp:LongTermContractsOrProgramsDateOfContractCancelled>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="-5">1900000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012" unitRef="CNY" decimals="0">7500000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="USD" decimals="0">3500000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember" unitRef="CNY" decimals="0">22000000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_FirstInstallmentMember" unitRef="USD" decimals="0">794000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_FirstInstallmentMember" unitRef="CNY" decimals="0">5000000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_SecondInstallmentMember" unitRef="USD" decimals="0">950000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_SecondInstallmentMember" unitRef="CNY" decimals="0">6000000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_ThirdInstallmentMember" unitRef="USD" decimals="0">1300000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_ThirdInstallmentMember" unitRef="CNY" decimals="0">8000000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_FourthInstallmentMember" unitRef="USD" decimals="0">476000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundable contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember_LongTermContractsOrProgramsInstallmentsAxis_FourthInstallmentMember" unitRef="CNY" decimals="0">3000000</tglp:LongTermContractsOrProgramsPurchasePriceRefundable>
<tglp:LongTermContractsOrProgramsPurchasePriceRefundableDescription contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_TonghuaAgreementMember">Pursuant to the Termination Agreement, Tonghua will refund prepayment of RMB 22,000,000 (approximate to $3.5 million) in four installments. The first installment of RMB5, 000,000 (approximately $794,000) will be refunded prior to August 30, 2012, the second installment of RM6, 000,000 (approximately $950,000) will be refunded prior to November 30, 2012, the third installment of RMB8,000,000 (approximately $1.3 million) will be refunded prior to February 28, 2013 and the last installment of RMB3,000,000 (approximately $476,000) will be refunded prior to May 30, 2013.</tglp:LongTermContractsOrProgramsPurchasePriceRefundableDescription>
<tglp:PaymentsForContractDeposits contextRef="Context_1ME_31-Mar-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="USD" decimals="0">215000</tglp:PaymentsForContractDeposits>
<tglp:PaymentsForContractDeposits contextRef="Context_1ME_31-Mar-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="CNY" decimals="0">1370000</tglp:PaymentsForContractDeposits>
<tglp:PaymentsForContractDeposits contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="CNY" decimals="0">3500000</tglp:PaymentsForContractDeposits>
<tglp:PaymentsForContractDeposits contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_YangshenWubaoPurchaseAgreementMember" unitRef="USD" decimals="0">475000</tglp:PaymentsForContractDeposits>
<tglp:PaymentsForContractDeposits contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_YangshenWubaoPurchaseAgreementMember" unitRef="CNY" decimals="0">3000000</tglp:PaymentsForContractDeposits>
<tglp:LongTermContractsOrProgramsPurchasePricePayableOnCommencementPercentage contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="pure" decimals="2">0.50</tglp:LongTermContractsOrProgramsPurchasePricePayableOnCommencementPercentage>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">4415426</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31-Mar-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember" unitRef="USD" decimals="0">4415426</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31-Mar-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_XinyuBreathSprayMember" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">5807881</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30-Sep-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember" unitRef="USD" decimals="0">4462731</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30-Sep-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_XinyuBreathSprayMember" unitRef="USD" decimals="0">1345150</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">374394</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">484001</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">4041032</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">5323880</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_31-Mar-2008_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_GovernmentMember" unitRef="USD" decimals="0">400000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_31-Mar-2008_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_GovernmentMember" unitRef="CNY" decimals="0">2700000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_Custom_31-Dec-2010_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember" unitRef="USD" decimals="0">1817541</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_Custom_31-Dec-2010_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember" unitRef="CNY" decimals="0">12000000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">1129237</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_FYE_31-Mar-2008_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_GovernmentMember">P50Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_Custom_31-Dec-2010_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_Custom_31-Mar-2011_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod contextRef="Context_FYE_31-Mar-2008_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_GovernmentMember">straight-line basis</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod contextRef="Context_Custom_31-Mar-2011_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember">straight-line basis</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember">straight-line basis</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
<us-gaap:FiniteLivedIntangibleAssetsAcquired contextRef="Context_Custom_31-Dec-2010_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember" unitRef="USD" decimals="0">3000000</us-gaap:FiniteLivedIntangibleAssetsAcquired>
<us-gaap:FiniteLivedIntangibleAssetsAcquired contextRef="Context_Custom_31-Dec-2010_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember" unitRef="CNY" decimals="0">20000000</us-gaap:FiniteLivedIntangibleAssetsAcquired>
<us-gaap:FiniteLivedIntangibleAssetsAcquired contextRef="Context_Custom_31-Mar-2011_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember" unitRef="USD" decimals="0">850000</us-gaap:FiniteLivedIntangibleAssetsAcquired>
<us-gaap:FiniteLivedIntangibleAssetsAcquired contextRef="Context_Custom_31-Mar-2011_FiniteLivedIntangibleAssetsByMajorClassAxis_UseRightsMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_IndividualMember" unitRef="CNY" decimals="0">5500000</us-gaap:FiniteLivedIntangibleAssetsAcquired>
<us-gaap:FiniteLivedIntangibleAssetsAcquired contextRef="Context_6ME_30-Sep-2011_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="CNY" decimals="0">8500000</us-gaap:FiniteLivedIntangibleAssetsAcquired>
<us-gaap:FiniteLivedIntangibleAssetsAcquired contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="USD" decimals="0">1345150</us-gaap:FiniteLivedIntangibleAssetsAcquired>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">-87538</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_HarbinTianmuRealEstateDevelopmentCoLtdMember" unitRef="USD" decimals="0" id="Item_10">-599151</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoMingliChairmanOfCompanyMember" unitRef="USD" decimals="0">570324</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_UsHuaSkyInternationalInvestmentLlcMember" unitRef="USD" decimals="0" id="Item_12">27727</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_TianmuInvestmentCoLtdMember" unitRef="USD" decimals="0" id="Item_14">-7829</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoYuanShareholderOfCompanyMember" unitRef="USD" decimals="0" id="Item_16">-78609</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">66209</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_HarbinTianmuRealEstateDevelopmentCoLtdMember" unitRef="USD" decimals="0" id="Item_18">-398260</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoMingliChairmanOfCompanyMember" unitRef="USD" decimals="0">570324</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_UsHuaSkyInternationalInvestmentLlcMember" unitRef="USD" decimals="0" id="Item_19">-23901</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_TianmuInvestmentCoLtdMember" unitRef="USD" decimals="0" id="Item_20">-4748</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent contextRef="Context_As_Of_30-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_YaoYuanShareholderOfCompanyMember" unitRef="USD" decimals="0" id="Item_21">-77206</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_6ME_30-Sep-2011" unitRef="shares" decimals="0">133333</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">20000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">1021313</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">187045</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-319368</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-84670</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">172125</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">106294</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">113357</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">983169</us-gaap:CurrentIncomeTaxExpenseBenefit>
<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">109298</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-2805</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">211673</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">3193681</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">666696</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">-275646</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-132282</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements contextRef="Context_6ME_30-Sep-2012" unitRef="pure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">1871117</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">1988399</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwardsExpirationDates contextRef="Context_6ME_30-Sep-2012">These carry forwards will expire between 2028 and 2030</us-gaap:OperatingLossCarryforwardsExpirationDates>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_6ME_30-Sep-2011" unitRef="pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_6ME_30-Sep-2012" unitRef="pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<tglp:ValueAddedTaxRate contextRef="Context_As_Of_30-Sep-2012" unitRef="pure" decimals="2">0.17</tglp:ValueAddedTaxRate>
<tglp:BusinessTaxRate contextRef="Context_As_Of_30-Sep-2012" unitRef="pure" decimals="2">0.05</tglp:BusinessTaxRate>
<tglp:CityConstructionTaxRate contextRef="Context_As_Of_30-Sep-2012" unitRef="pure" decimals="2">0.07</tglp:CityConstructionTaxRate>
<tglp:EducationFeesBasedOnVatRate contextRef="Context_As_Of_30-Sep-2012" unitRef="pure" decimals="2">0.05</tglp:EducationFeesBasedOnVatRate>
<tglp:OperatingLeaseAgreementDate contextRef="Context_6ME_30-Sep-2012">2012-06-28</tglp:OperatingLeaseAgreementDate>
<tglp:OperatingLeasePeriodicPayment contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">1749</tglp:OperatingLeasePeriodicPayment>
<tglp:OperatingLeaseFrequencyOfPeriodicPayment contextRef="Context_6ME_30-Sep-2012">monthly</tglp:OperatingLeaseFrequencyOfPeriodicPayment>
<tglp:OperatingLeasePaymentTerms contextRef="Context_6ME_30-Sep-2012">Pursuant to the lease agreement, the term of the lease is from August 2012 to July 2013</tglp:OperatingLeasePaymentTerms>
<tglp:PaymentsForSecurityDeposits contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">3498</tglp:PaymentsForSecurityDeposits>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30-Sep-2012" unitRef="USD" decimals="0">12243</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="Context_As_Of_30-Sep-2012" unitRef="pure" decimals="2">1.00</us-gaap:MinorityInterestOwnershipPercentageByParent>
<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 6pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 48px;"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;CONCENTRATION OF CREDIT RISKS&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;For the three months ended September 30, 2012, the Company&amp;#8217;s Panax and Radix Polygoni Capsule&lt;b&gt; &lt;/b&gt;represented 98% of the total sales, as compared to four products manufactured by the Company, including Panax and Radix Polygoni Capsule, Antihyperlipidemics, Calcium Gluconate Oral Liquid, and Anti-bacterial Mouthwash, represented 36.09%, 21.39%, 18.32% , and 18.97% respectively of the total sales for the three months ended September 30, 2011.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the six months ended September 30, 2012, 98.07% of sales were generated from one major distributor. During the six months ended September 30, 2011, 10.33% of sales were generated from one major distributor.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;For the six months ended September 30, 2012, Panax and Radix Polygoni Capsule represented 98% of the total sales, as compared four products manufactured by the Company, including Panax and Radix Polygoni Capsule, Antihyperlipidemics, Calcium Gluconate Oral Liquid, and Anti-bacterial Mouthwash, represented 45.52%, 21.12%, 13.96% , and 14.82% respectively of the total sales for the six months ended September 30, 2011.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>


<tglp:IncreaseDecreaseInAdvancesFromSupplies contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">-76697</tglp:IncreaseDecreaseInAdvancesFromSupplies>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_6ME_30-Sep-2012">&lt;table style="font: 10pt/normal times new roman, times, serif; margin-top: 0px; margin-bottom: 6pt; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="width: 48px; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;LAND USE RIGHTS/INTANGIBLE ASSETS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The executive offices and manufacturing facilities of the Company&amp;#8217;s subsidiary Tianmu Pharmaceuticals are located in the Limin Pharmaceutical Technology Park in the City of Harbin, which is the capital of Heilongjiang Province in The People&amp;#8217;s Republic of China. In 2008, Tianmu Pharmaceuticals paid RMB 2.7 million (approximate to $400,000) to local government to obtain a land use right of 50,000 square meters for 50 years for manufacturing purposes. The Company amortizes this land use right on a straight-line basis over 50 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On December 20, 2010, the Company entered into a contract with a non-affiliated individual to acquire rights to use a parcel of land and fixtures thereon for twenty years (from December 20, 2010 to December 30, 2030) for RMB20 million (approximately $3 million). RMB12 million (equivalent to $1,817,541) was paid upon execution of the contract in December 2010. The balance was required to be paid within 20 days after the conveyance of a list of land and fixtures. Due to the nature of the subject parcel of land, there is no PRC government approval or recording required for the transfer of land use right. The Company paid the outstanding balance under the contract on February 21, 2011 and the transfer was concluded in March 2011. As such, the total contract price was recorded as long-term assets and is amortized over the twenty years use right period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In March 2011, the Company entered into a supplemental contract with the same third-party to acquire a nearby fish pond for twenty years with total contract price of RMB 5.5 million (approximate to $0.85 million). The Company will use this fish pond to provide water supply to the planted traditional Chinese medicine. Total amount of this contract is being amortized on a straight-line basis over twenty years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On April 30, 2012, the Company entered into Xinyu Breath Spray purchase agreement with Harbin Healthcare Product Company (See note 4). Total amount of the purchase price of RMB8,500,000 (approximately $1,345,150) was amortized on a straight-line basis over 10 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of September 30, 2012 and March 31, 2012, intangible assets consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;September 30, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;March 31, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 70%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Land use rights&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,462,731&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,415,426&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Xinyu breath spray&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,345,150&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,807,881&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,415,426&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Less: Accumulated amortization&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(484,001&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(374,394&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,323,880&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,041,032&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The amortization expense for the six months ended September 30, 2012 and 2011 was $105,679&lt;font style="color: black;"&gt; and $103,286 respectively.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_30-Sep-2011_ProductOrServiceAxis_PanaxAndRadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.3609</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_30-Sep-2011_ProductOrServiceAxis_AntihyperlipidemicsMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.2139</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_30-Sep-2011_ProductOrServiceAxis_CalciumGluconateOralLiquidMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.1832</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_30-Sep-2011_ProductOrServiceAxis_AntiBacterialMouthwashMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.1897</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_6ME_30-Sep-2011_ProductOrServiceAxis_PanaxAndRadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.4552</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_6ME_30-Sep-2011_ProductOrServiceAxis_AntihyperlipidemicsMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.2112</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_6ME_30-Sep-2011_ProductOrServiceAxis_CalciumGluconateOralLiquidMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.1396</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_6ME_30-Sep-2011_ProductOrServiceAxis_AntiBacterialMouthwashMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="4">0.1482</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_6ME_30-Sep-2011_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember" unitRef="pure" decimals="4">0.1033</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_30-Sep-2012_ProductOrServiceAxis_RadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="2">0.98</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_6ME_30-Sep-2012_ProductOrServiceAxis_RadixPolygoniCapsuleMember_ConcentrationRiskByTypeAxis_ProductConcentrationRiskMember" unitRef="pure" decimals="2">0.98</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_6ME_30-Sep-2012_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConcentrationRiskByBenchmarkAxis_SalesRevenueGoodsNetMember" unitRef="pure" decimals="4">0.9807</us-gaap:ConcentrationRiskPercentage1>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Item_1" xlink:label="lab_Item_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_1" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_3" xlink:label="lab_Item_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_3" xlink:to="Footnote_4" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_5" xlink:label="lab_Item_5"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_5" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_7" xlink:label="lab_Item_7"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_7" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_8" xlink:label="lab_Item_8"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_8" xlink:to="Footnote_4" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_9" xlink:label="lab_Item_9"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_9" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_10" xlink:label="lab_Item_10"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_10" xlink:to="Footnote_11" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_12" xlink:label="lab_Item_12"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_12" xlink:to="Footnote_13" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_14" xlink:label="lab_Item_14"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_14" xlink:to="Footnote_15" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_16" xlink:label="lab_Item_16"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_16" xlink:to="Footnote_17" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_18" xlink:label="lab_Item_18"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_18" xlink:to="Footnote_11" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_19" xlink:label="lab_Item_19"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_19" xlink:to="Footnote_13" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_20" xlink:label="lab_Item_20"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_20" xlink:to="Footnote_15" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_21" xlink:label="lab_Item_21"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_21" xlink:to="Footnote_17" order="1.0"/>
<link:footnote xlink:type="resource" xlink:label="Footnote_2" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">On March 21, 2010, the Company entered into a New Drug Assignment Agreement (the "Tonghua Agreement") with TonghuaYisheng Pharmaceuticals Company Limited ("Tonghua") pursuant to which the Company agreed to purchase a new drug candidate, called Nafarelin, from Tonghua for a purchase price of RMB33,000,000 (approximately $4.85 million). The total purchase price is payable in three installments: 33% of the total purchase price (approximately $1.6 million) was paid upon execution of the Tonghua Agreement in March 2010; another 33% (approximately $1.6 million) was paid in March 2011 (although it is required to be paid upon conclusion of third clinical trial for the product pursuant to the terms of the Tonghua Agreement) and the balance is payable upon conclusion of the transfer. Nafarelin is a proposed treatment for endometriosis and prostate cancer. At a minimum, completion of the third phase clinical trail is a pre-condition to receipt of the New Drug Approval Certificate from the SFDA. The SFDA new drug approval procedure is separate and distinct from the patent prosecution procedure. To date, neither Tonghua nor the Company has applied or intend to apply for patent protection for Nafarelin or the formula or process related to Nafarelin. Once Tonghua is granted the New Drug Approval Certificate for Nafarelin, according to pharmaceutical laws of PRC, the Company, as the assignee of the New Drug Approved Certificate, shall receive 4 years of exclusive protection. As described below, the Company regards such protection period as the appropriate amortization period. The patent protection is irrelevant for purposes of amortization in determining the life of the drug as the Company will not apply for patent protection for Nafarelin. The Company is not be responsible for conducting or paying for any clinical trial and/or research and development in connection with the new drug application for Nafarelin. Pursuant to the Tonghua Agreement, Tonghua shall continue the research, development and clinical trial work for Nafarelin until the SFDA grants the New Drug Approval Certificate and the product is ready to be marketed. Tonghua is listed as the applicant for the SFDA new drug approval process for this product. Once SFDA approval is obtained, the Company will be able to consummate the assignment and enjoy the protection afforded by the New Drug Approval Certificate. In addition, the Company's ability to commercialize this new product also requires assistance and cooperation from Tonghua, which Tonghua is obligated to provide to us under the Tonghua Agreement. Under PRC law, the SFDA's New Drug Approval Certificate grants certain exclusive protections to approved new drugs, meaning that the subject formula may not be manufactured by other parties in China. The exclusive protection periods for the new drugs vary from 4 to 12 years depending on the category of the new drug. Because the Company shall be the beneficiary of the exclusive protection during the applicable period (the so-called "new drug approval period"), upon consummation of the transaction contemplated by the Tonghua Agreement, the Company will regard the protection period as the appropriate amortization period. Based on ASC 805-50-30 "Initial Measurement on Acquisition of Assets Rather Than a Business" and ASC350-30 "General Intangibles Other Than Goodwill", the total payment pursuant to the Tonghua Agreement will be recorded as an intangible asset once the Company obtains the SFDA New Drug Approval Certificate and will be amortized over the term of the new drug protection period. Based on a written mutual understanding between the Company and Tonghua, any payments the Company made to Tonghua under the Tonghua Agreement will be refunded if SFDA approval is not obtained for Nafarelin. Such mutual understanding, although the Company believes to be binding, was not explicitly stipulated in the Tonghua Agreement or otherwise memorialized. As such, the first two installment under the Tonghua Agreement was accounted as a deposit and the remaining last installment payment will be also accounted as deposits until the New Drug Approval Certificate is obtained, at which point the total payment will be recorded as intangible asset and amortized over the term of the new drug protection period.The Tonghua Agreement also provides that the Company and Tonghua will compensate one another for all losses incurred by the other party if the purchase is not concluded due to reasons attributable to the offending party. On June 6, 2012, the Company entered into a Termination Agreement with Tonghua pursuant to which the Tonghua Agreement was terminated. Pursuant to the Termination Agreement, Tonghua will refund prepayment of RMB 22,000,000 (approximate to $3.5 million) in four installments. The first installment of RMB5, 000,000 (approximately $794,000) will be refunded prior to August 30, 2012, the second installment of RM6, 000,000 (approximately $950,000) will be refunded prior to November 30, 2012, the third installment of RMB8,000,000 (approximately $1.3 million) will be refunded prior to February 28, 2013 and the last installment of RMB3,000,000 (approximately $476,000) will be refunded prior to May 30, 2013. During six months ended September 30, 2012, the Company received refund payment of RMB7,500,000 (approximately $1.19 million).</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_4" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">On April 30, 2012, the Company entered into Xinyu Breath Spray purchase agreement with Harbin Junde Healthcare Product Company. Pursuant to the agreement, the total purchase price is RMB8,500,000 (approximately $1.33 million). The Company will pay 50% of the purchase price after commencement of the Xinyu Breath Spray purchase agreement and pay the rest of the purchase price after the Company manufactured three batches of Xinyu Breath Spray that meet the quality standards of the product. The Company paid RMB1,370,000 (approximately $215,000) on March 29, 2012, RMB3,630,000 (approximately $568,000) on May 30, 2012 and paid the balance due of RMB3,500,000 (approximately $554,000) in August 2012. Based on ASC 805-50-30 Initial Measurement on Acquisition of Assets Rather Than a Business and ASC350-30 General Intangibles Other Than Goodwill, the total payment pursuant to the agreement with Harbin Junde Healthcare Product Company is recorded as an intangible asset and will be amortized over the estimated useful life of this product. (See note 5)</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_6" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">On August 10, 2012, the Company entered into Yangshen Wubao purchase agreement with Harbin Junde Healthcare product Company. Pursuant to the agreement, the Company will acquire the exclusive right to manufacture the Yangshen Wubao at the total purchase price of RMB13,000,000 (approximately $2.06 million). The Company paid RMB3,000,000 (approximately $475,000) as the deposit at the closing of Yangsheng Wubao purchase agreement. The rest of the purchase price will be paid in installments according to the payment schedule. The Company is planning to manufacture this product using a subcontractor in the United States. Currently, the Company is in the process of testing this product. Based on ASC 805-50-30 Initial Measurement on Acquisition of Assets Rather Than a Business and ASC350-30 General Intangibles Other Than Goodwill, the total payment pursuant to the agreement will be recorded as an intangible asset once the company finish the acquisition process and is being amortized over the life of this product.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_11" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Harbin Tianmu Real Estate Development Co., Ltd. is an entity owned by our Chairman, Mr. Mingli Yao.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_13" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">US Hua Sky International Investment LLC is an entity owned by our Chairman, Mr. Mingli Yao</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_15" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Tianmu Investment Co., Ltd. is an entity partially owned by our Chairman, Mr. Mingli Yao.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_17" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Ms. Yuan Yao is the daughter of Mr. Mingli Yao.</link:footnote>
</link:footnoteLink>
<xbrli:context id="Context_As_Of_08-Nov-2012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2012-11-08</xbrli:instant></xbrli:period></xbrli:context>
	<tglp:TransferFromContractDepositToIntangibleAssets contextRef="Context_6ME_30-Sep-2011" unitRef="USD" decimals="0">0</tglp:TransferFromContractDepositToIntangibleAssets>
<tglp:TransferFromContractDepositToIntangibleAssets contextRef="Context_6ME_30-Sep-2012" unitRef="USD" decimals="0">216978</tglp:TransferFromContractDepositToIntangibleAssets>
<tglp:PaymentsForContractDeposits contextRef="Context_6ME_30-Sep-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="USD" decimals="0">554000</tglp:PaymentsForContractDeposits>
<xbrli:context id="Context_1ME_31-Mar-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:XinyuBreathSprayPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-03-01</xbrli:startDate><xbrli:endDate>2012-03-31</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_1ME_31-May-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tglp:LongTermContractsOrProgramsAxis">tglp:XinyuBreathSprayPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-05-01</xbrli:startDate><xbrli:endDate>2012-05-31</xbrli:endDate></xbrli:period></xbrli:context>
	<tglp:PaymentsForContractDeposits contextRef="Context_1ME_31-May-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="CNY" decimals="0">3630000</tglp:PaymentsForContractDeposits>
<tglp:PaymentsForContractDeposits contextRef="Context_1ME_31-May-2012_LongTermContractsOrProgramsAxis_XinyuBreathSprayPurchaseAgreementMember" unitRef="USD" decimals="0">568000</tglp:PaymentsForContractDeposits>
<xbrli:context id="Context_1ME_30-Sep-2012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-09-01</xbrli:startDate><xbrli:endDate>2012-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_1ME_30-Sep-2012" unitRef="shares" decimals="0">1300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_1ME_30-Sep-2012" unitRef="USD" decimals="0">195000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<xbrli:context id="Context_As_Of_31-Mar-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_XinyuBreathSprayMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tglp:XinyuBreathSprayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-03-31</xbrli:instant></xbrli:period></xbrli:context>
	<xbrli:context id="Context_As_Of_30-Sep-2012_FiniteLivedIntangibleAssetsByMajorClassAxis_XinyuBreathSprayMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001052284</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tglp:XinyuBreathSprayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-09-30</xbrli:instant></xbrli:period></xbrli:context>
	</xbrli:xbrl>